Search

Search Constraints

You searched for: Author/Creator Walewski, Jan

Search Results

22. Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma. (1st April 2022)

23. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. (July 2020)

24. Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs. (5th February 2021)

25. Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis. Issue 4 (April 2013)

26. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma. (May 2016)

27. Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Issue 12 (14th October 2020)

28. Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Issue 12 (14th October 2020)

29. Primary refractory multiple myeloma: a real-world experience with 85 cases. Issue 12 (14th October 2020)

30. Primary refractory multiple myeloma: a real-world experience with 85 cases. Issue 12 (14th October 2020)